Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

This week’s Bulls N’ Bears Runner of the Week is… Kalgoorlie Gold Mining. The company’s share price rocketed after a new ...

Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...

The Dwarf 3 is great for astrophotography beginners, but it also has lots of useful tools for more experienced hobbyists.

Mikko Koskimies, CEO of eQ Plc and Managing Director of eQ Asset Management Ltd, left these positions at the end of October ...

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...

MST Financial is managing the raise and has split it into two tranches. Shares were placed in a trading halt on Thursday.

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

Facilities use transport of solids, new technology, and improved automation to experience significant waste handling savings.

Strange, is it not? No "disproportionate response" is mentioned in the UN about this lopsided equation. And just look at the ...